HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT

摘要

The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) virus (Heat-iMVA) or Heat-inactivated vaccinia virus as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies for use as a cancer immunotherapeutic.